Ipilimumab

被引:8
作者
不详
机构
关键词
general; Ipilimumab; Lymphoma; Malignant-melanoma; Non-small-cell-lung-cancer; Prostate-cancer; Research-and-development; treatment;
D O I
10.2165/11584510-000000000-00000
中图分类号
学科分类号
摘要
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II for lymphoma and non-small cell lung cancer in the US and other areas of the world. This review discusses the key development milestones and therapeutic trials on this drug to date. © 2010 Adis Data Information BV. All rights reserved.
引用
收藏
页码:97 / 110
页数:13
相关论文
共 52 条
[1]  
A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn A Higher Patient Share in the U. S. Than in Europe, (2009)
[2]  
Bristol-myers Squibb Company. Bristol-myers Squibb Completes Acquisition of Medarex, (2009)
[3]  
Bristol-myers Squibb and Medarex Global Development and Commercialization Collaboration for MDX-010 Becomes Effective, (2005)
[4]  
Cell. Genesys Announces Tender Offer Results While Continuing to Pursue Strategic Alternatives, (2009)
[5]  
The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-treated Patients with Metastatic Melanoma, (2010)
[6]  
Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-treated Patients with Metastatic Melanoma, (2010)
[7]  
Medarex Receives FDA Fast Track Designation for MDX-010 Treatment of Metastatic Melanoma, (2004)
[8]  
Medarex Commences Enrollment in Phase III Clinical Trial for MDX-010 in Metastatic Melanoma, (2004)
[9]  
Medarex Announces Special Protocol Assessment Agreement with FDA to Initiate Phase III Clinical Trial for MDX-010 in Metastatic Melanoma, (2004)
[10]  
Top-line Data Available From Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma, (2007)